Heparin and nitric oxide (NO) attenuate changes to the pulmonary vasculature caused by prolonged hypoxia. Heparin may increase NO; therefore, we hypothesized that heparin may attenuate hypoxia-induced pulmonary vascular remodeling via a NOmediated mechanism. In vivo, rats were exposed to normoxia (N) or hypoxia (H, 10% O 2 ) with or without heparin (1200 U/kg/d) and/or the NO synthase (NOS) inhibitor N G -nitro-L-arginine (L-NAME, 20 mg/kg/d) for 3 d or 3 wk. Heparin attenuated increases in pulmonary artery pressure, the percent of muscular pulmonary vessels and their medial thickness induced by 3 weeks of H. Importantly, while L-NAME alone had no effect, it prevented these effects of heparin on vascular remodeling. In H lungs, heparin increased NOS activity and 3'5'cyclic guanosine monophosphate (cGMP) levels at 3 d and 3 wks, and endothelial NOS protein expression at 3 d but not at 3 wk. In vitro, heparin (10 and 100 U/kg/ml) increased cGMP levels after 10 min and 24 hr in N and anoxic (0% O 2 ) endothelial cell /smooth muscle cell (SMC) coculture. SMC proliferation, assessed by BrdU-incorporation during a 3 hr incubation period, was decreased by heparin under N, but not anoxic condition. The anti-proliferative effects of heparin were not altered by L-NAME. In conclusion, the in vivo results suggest that attenuation of hypoxia-induced pulmonary vascular remodeling by heparin is NO-mediated. Heparin increases cGMP in vitro, however, the heparin-induced decrease in SMC proliferation in the coculture model appears to be NO-independent. 
Introduction
Heparin inhibits the development of pulmonary hypertension and vascular remodeling associated with prolonged hypoxia, however, the mechanism is not completely understood (8, 13, 15, 30) . Continuous intravenous heparin (300 U/kg/d) infusion for 10 days of hypoxic exposure has been shown to attenuate increases in pulmonary artery pressure (PAP), right ventricular hypertrophy, and pulmonary vascular remodeling in mice (8). This attenuation does not appear to be related to an anticoagulant effect of heparin, since warfarin, also an anticoagulant, does not attenuate hypoxic pulmonary hypertension (11) . The effect of heparin is specific to the pulmonary circulation since doses of heparin that decrease hypoxic pulmonary hypertension do not affect systemic hypertension (19) . The effectiveness of different preparations of heparin to inhibit the development of hypoxic pulmonary hypertension in vivo appears to be related to its antiproliferative potency in vitro (30) .
Heparin may attenuate the development of hypoxia-induced pulmonary vascular remodeling by inhibiting smooth muscle cell growth. In vitro studies have demonstrated that heparin inhibits rat smooth muscle cell proliferation (24, 30) . Heparin has also been shown to have properties that specifically affect the vascular endothelium, which may act on the vascular smooth muscle. Heparin potentiates acetylcholine stimulated production of 3'5'cyclic guanosine monophosphate (cGMP) and nitric oxide (NO) formation as determined by nitrite/nitrate (NO 2 /NO 3 ) levels in rat cultured aortic endothelial cells (23) .
However, Upchurch et al. (31) reported that high dose heparin increases in vitro platelet aggregation in media conditioned by bovine aortic endothelial cells by decreasing endothelial NO production.
Increases in NO secondary to heparin may play an important mechanistic role in regulation of the pulmonary vasculature. Hypoxic pulmonary hypertension is attenuated by exogenous sources of NO. Inhaled NO (18, 27) , L-arginine (23) , and inhibitors of cGMP degradation (3) decrease pulmonary vascular remodeling and attenuate increases in PAP secondary to hypoxia. Additionally, endogenous NO is a negative regulator of vascular smooth muscle proliferation (25) .
This study investigated the hypothesis that heparin-induced attenuation of hypoxic pulmonary vascular remodeling is NO-mediated. In rats, the effect of a continuous infusion of heparin (1200 U/kg/d) on pulmonary vascular remodeling was evaluated after 3 days and 3 weeks of exposure to 10% oxygen. The role of NO in heparin-induced attenuation of pulmonary vascular remodeling was determined by infusing the nitric oxide synthase (NOS) inhibitor N G -nitro-L-arginine (L-NAME).
Endothelial eNOS protein, NOS activity, and cGMP were measured to determine the effects of heparin on the NO/cGMP pathway in the lungs. In vitro, the effects of heparin on cGMP levels and smooth muscle cell proliferation were studied in an endothelial cell/smooth muscle cell (EC/SMC) coculture model under normoxic and anoxic conditions. Maintenance of the hypoxic environment was performed as previously described (27) . Rats were placed in a Plexiglass chamber and oxygen levels were regulated with a Pro:Ox Model 350 unit (Reming Bioinstrument Co., Redfield, New York) and maintained at 10% O 2 by infusion of N 2 .
Methods

In vivo experiments
Following 3 days or 3 weeks of environmental exposure, the rats were removed from the chambers and immediately anesthetized using 0.4 g urethane and 30 mg α- To quantify smooth muscle cell DNA synthesis, the percent of BRDU-positive, α-actin positive, vWF-negative nuclei per total nuclei was determined for each well. At least 500 but not more than 600 total nuclei were counted per well using a FITC filter and a 20x objective on a Zeiss Axioscope (Thornwood, NY). The image was observed on a Sony monitor connected to the Axioscope via a video intensifier (Dage MTI, Michigan City, IN) in series with a CCD camera (Dage MTI). Following counting total nuclei in a given field of view, BrdU-positive cells were counted using an AMCA filter. Fields of view were selected for counting if the total number of SMC nuclei was at least 10 but no greater than 100 to avoid variability in proliferation associated with local seeding density.
Optimus (v6.1) software package.
Data Analysis
BW, RV/(LV+S) and PAP were determined from the mean of all rats within a group. Percent muscularization (%M) was determined for 50 vessels examined in each lung section. Percent thickness (%T) was assessed for each muscular vessel and the mean %T of all muscular vessels from an individual lung section was used in determining the group mean. Densitometric results from western blots were normalized to normoxic control values. SMC proliferation as assayed by BrdU-incorporation was determined by the percent BrdU+ SMC per total SMC nuclei (%BrdU+). Data were analyzed by oneway ANOVA with SigmaStat software (Jandel Scientific). Individual comparisons between group means were made with a t-test with Bonferroni's correction factor for multiple tests. Significance was assumed at p < 0.05. Data are expressed as mean ± standard error of the mean.
Results
In vivo results
Pilot studies determined that there were no significant differences in PAP or (RV/LV+S) between rats with saline filled osmotic pumps and rats without pumps in either normoxic or hypoxic rats after three weeks.
After 3 days of hypoxia, the (RV/LV+S) was unaltered as compared to normoxia increase in hypoxic rats, the (RV/LV+S) remained greater than normoxic controls. L-NAME alone did not significantly alter (RV/LV+S) in hypoxic rats at three weeks, however, L-NAME prevented the attenuation of (RV/LV+S) caused by heparin.
Three days of hypoxia in the presence (11±2 mmHg) or absence (10±2 mmHg) of heparin had no effect on PAP as compared to normoxia (10±2 mmHg). While L-NAME alone (14±1 mmHg) had no effect on hypoxic rats, L-NAME and heparin significantly increased PAP (20±3 mmHg) as compared to three day hypoxic controls. After three weeks of hypoxia, PAP was significantly increased compared to normoxic controls (figure 1). Heparin significantly attenuated the increase in PAP as compared to hypoxic controls. While L-NAME alone had no effect in hypoxic rats, L-NAME prevented the attenuation of PAP secondary to heparin.
Vascular remodeling was assessed by the proportion of pulmonary vessels classified as muscular (%M) and the thickness of the medial layer of muscular vessels as a percent of their short-axis diameter (%T). After three days of exposure, hypoxia with or without heparin or L-NAME had no significant effect on %M or %T. After three weeks of hypoxia, both %M and %T were significantly increased (figure 2). Heparin significantly attenuated this increase. L-NAME attenuated the effects of heparin in hypoxic rats, whereas L-NAME alone did not significantly affect %M or %T.
NOS activity was significantly increased by hypoxia after three days and three weeks compared to normoxic controls. After three days and three weeks heparin significantly increased NOS activity compared to hypoxia alone. There was no difference between the three day and three week heparin plus hypoxia groups. The cGMP levels were also significantly increased by hypoxia after three days and three weeks (three weeks > three days) compared to normoxic controls. Heparin increased cGMP levels at three days and three weeks compared to hypoxia alone, with the three week heparin plus hypoxic values greater than the three day heparin plus hypoxic group.
L-NAME abolished NOS activity and cGMP levels (figure 3).
The eNOS protein level was significantly increased by hypoxia after three days and three weeks as compared to normoxic controls (figure 3). Heparin increased eNOS at three days as compared to hypoxia alone. However, after three weeks eNOS was not different from normoxic controls. The eNOS level in the hypoxic group with L-NAME and heparin was not different from hypoxia alone at either three days or three weeks but was greater than normoxic controls. L-NAME had no effect on eNOS levels in hypoxic rats.
In vitro results
The cGMP levels were evaluated in an EC/SMC coculture after incubation periods of 10 min and 24 hr under normoxic and anoxic conditions. After a 10 minute normoxic or anoxic incubation period, endothelial-dependent and -independent positive controls, bradykinin and sodium nitroprusside, increased cGMP levels 5-fold and 2-fold, respectively. Heparin, at concentrations of 10 and 100 U/ml, significantly increased cGMP levels after 10 min of normoxia and hypoxia as compared to normoxic controls (figure 4). There was no significant difference between the two concentrations. The cGMP levels after 10 min were not different between anoxic and normoxic groups.
Following 24 hr of normoxia the cGMP levels were significantly increased compared to 10 min normoxia for all groups. The cGMP levels were significantly less for all anoxic groups compared to the normoxic groups. After 24 hr, heparin, at concentrations of 10 and 100 U/ml, significantly increased cGMP levels under both normoxic and anoxic conditions. L-NAME decreased the cGMP levels to near zero.
The SMC proliferation was assessed by the percent of smooth muscle cell nuclei staining positive for BrdU incorporation after 3 hours. Heparin significantly decreased proliferation during the normoxic incubation period as compared to normoxic controls (figure 5). L-NAME alone had no significant effect in normoxic conditions and L-NAME did not reverse the effects of heparin. Anoxia significantly decreased smooth muscle cell proliferation as compared to normoxic controls. Heparin and/or L-NAME did not significantly affect proliferation under anoxic conditions.
Discussion
This in vivo and in vitro study investigated if the mechanisms by which heparin attenuates hypoxic pulmonary vascular remodeling are mediated by NO. Heparin attenuated the increase in PAP, (RV/LV+S), %M and %T associated with three weeks of hypoxia. Importantly, NOS inhibition with L-NAME prevented this attenuation secondary to heparin. A role for NO is further suggested by the observation that heparin increased lung NOS activity and cGMP levels at three days and three weeks, and increased eNOS protein levels at three days. In cocultures heparin increased cGMP levels, however, heparin decreased cell proliferation by a mechanism which appears to be NO-independent.
Heparin significantly attenuated the increase in %M and %T associated with three weeks of hypoxia, but not three days of hypoxia. The results at three weeks are consistent with other studies, whereas the lack of an effect at three days is most likely L-NAME alone did not significantly affect pulmonary vascular remodeling in hypoxic rats. While L-NAME has previously been shown to acutely increase PAP in normal and hypoxic rats (27) , chronic L-NAME does not appear to alter pulmonary vascular remodeling after three weeks of hypoxia. This is consistent with Hampl et al.
(9) who reported that chronic hypoxia, but not L-NAME, induced pulmonary vascular remodeling. L-NAME alone did not alter PAP at three days or weeks, however, after three days the PAP was increased in the heparin plus L-NAME hypoxic rats. L-NAME is known to cause greater vasoconstriction in the presence of elevated NO levels (27) , a finding which occurs with hypoxia plus heparin at three days. However, this vasoconstriction is not apparent at three weeks as measured by PAP.
The most important finding in this study is that L-NAME prevented the effect of heparin on PAP, (RV/LV+S), %T, and %M in three week hypoxic rats. When administered alone, however, L-NAME did not have a significant effect on these parameters. These results suggest the ability of heparin to attenuate pulmonary vascular remodeling in hypoxic rats is dependent on NO. Previous studies in guinea pigs by
Hassoun (11) and Thompson (30) indicate that the ability of heparin to attenuate pulmonary vascular remodeling is not related to heparin's anticoagulant effects. Heparin may decrease pulmonary vascular remodeling by increasing NO, which causes both vasodilation and antiproliferative effects. Studies on human veins suggest heparin stimulates NO and subsequently induces vasodilation. The decrease in vascular tone caused by heparin has been shown to be attenuated by the NO/cGMP inhibitors L-NMMA (29) and methylene blue (12) . Heparin may also modulate smooth muscle cell proliferation by an NO-mediated mechanism. The anti-mitogenic effects of NO on SMC have been well documented in vivo and in vitro ( 6, 7) . Mechanisms of action are likely to include both direct effects, which may be both cGMP-dependent and cGMP-independent, and indirect effects on factors such as SMC migration and death (12).
Our study indicates that the NO/cGMP pathway is stimulated by heparin in vivo.
Heparin significantly increased lung NOS activity and cGMP levels at three days and three weeks, and eNOS protein levels after three days. This increase in NOS activity, eNOS protein, and cGMP was greater than for hypoxia alone, a factor which has previously been shown to stimulate the NO/cGMP pathway (32) . is unlikely that iNOS plays a significant role since our previous studies have indicated that it is minimally present compared to eNOS in normoxic or hypoxic rats (5).
While heparin increased lung NOS activity and cGMP levels at both three days and three weeks, eNOS protein levels were increased at three days but decreased at three weeks. The decreased eNOS at three weeks may be related to negative feedback of increased NO on eNOS protein (26) . The increase in NOS activity at three weeks may explain the increase in cGMP levels despite the decrease in eNOS protein. Stimulation of the NO/cGMP pathway by heparin was completely abolished by L-NAME as measured by NOS activity and cGMP levels, which indicates the effectiveness of L-NAME in blocking the NO/cGMP pathway in these experiments. This observation, in conjunction with data demonstrating that L-NAME attenuated the effects of heparin in vivo, strongly suggests an important role of NO in heparin-induced attenuation of hypoxic pulmonary vascular remodeling.
The effect of heparin on NO in an EC/SMC coculture was indirectly assayed by measuring cGMP levels. The decreased cGMP levels associated with anoxia is consistent with reports showing an inhibitory effect of hypoxia on eNOS mRNA levels and cGMP production in human umbilical vein endothelial cells after 24-48 hours (22) and bovine pulmonary endothelial cells (21) . Importantly, heparin (10 and 100 U/ml) significantly increased cGMP levels after 10 minutes and 24 hours incubation in both normoxic and anoxic cells. While increased cGMP production at 24 hrs may be a consequence of induction of NOS protein expression (19) , the increase found after 10 minutes is likely a result of increased eNOS activity (16). While the effect of heparin on cGMP production under anoxic conditions has not been previously investigated, our results demonstrate that heparin increases cGMP levels in the in vitro coculture model to a similar extent in both anoxic and normoxic conditions.
The effects of heparin and NO inhibition on smooth muscle cell proliferation in the EC/SMC coculture model were determined indirectly by measuring BrdU incorporation. Heparin significantly decreased smooth muscle cell proliferation under normoxic conditions. This is consistent with the in vivo results and suggests that heparin may attenuate vascular remodeling by inhibiting smooth muscle cell proliferation.
However, in contrast to the in vivo results, L-NAME did not significantly alter the effects of heparin on proliferation in coculture despite blocking the increase in cGMP. This result suggests that inhibition of smooth muscle cell proliferation by heparin may not be mediated by NO. While these results are in apparent conflict with the in vivo results that suggest the mechanism of action of heparin is NO mediated, it is possible that the action of heparin is not solely mediated by NO. The studies by Tangphao and Hawari in human veins proposed that heparin-induced vasodilation is dependent on increased bioavailability of NO (12, 29) . This speculation is supported by a recent finding that heparin inhibits the generation of reactive oxygen species which bind NO and reduce the bioavailability of NO (4). It is also likely that the presence of shear stress and pressure in vivo contribute to differences with in vitro results. In contrast to its antiproliferative effect in normoxic conditions, heparin had no effect on SMC proliferation in anoxia. However, this may reflect the dramatic decrease in cell proliferation secondary to anoxia that does not allow for unmasking of the effects of heparin in this model.
In conclusion, the in vivo portion of this study suggests that the attenuation of weeks as compared to hypoxic control. + denotes 3 week greater than 3 day. L-NAME abolished NOS activity and cGMP but had no effect on eNOS protein levels. Data are mean±SEM. Figure 4 . cGMP levels after 10 minutes (top) and 24 hours (bottom) in EC/SMC coculture after exposure to heparin. * denotes that heparin significantly increased cGMP levels in normoxic (grey) and hypoxic (white) coculture at concentrations of 10 and 100 U/ml. Data are mean±SEM. Figure 5 . SMC proliferation after exposure to heparin and L-NAME. # denotes that anoxia (white) decreases SMC BrDU incorporation as compared to normoxia (grey). * denotes that BrDU incorporation is decreased by heparin alone and with heparin + L-NAME in normoxia as compared to control. Heparin and/or L-NAME had no effect in anoxia as compared to anoxia control. 
